Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system – cells, tissue, or organisms – and asking the question, did this entity affect the phenotype?… Read More
Meet Stunner: The One-Shot Protein Concentration and Sizing Combo Sponsored by Unchained Labs Stunner pulls double-duty so you don’t have to. It’s the one and only system that combines high-speed UV/Vis spectral analysis and Dynamic Light Scattering (DLS) for quantifying concentration and nailing down protein stability. Read More
Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver… Read More
Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70… Read More
Gaining Insights Into Disease Biology for Target Identification and Validation Sponsored by Agilent Dysfunctional energy metabolism is associated with many different diseases. As such, metabolic modulation is a promising avenue for novel targets in cancer, immunology, and neurological disease. Learn how live-cell metabolic measurements generate critical… Read More
New brand promise, new logo, new colors – Sartorius looks different today. A leading international partner of life science research and the biopharmaceutical industry, the company has revised its brand look. At the focus of this relaunch is Sartorius’ new brand promise that it summarizes in… Read More
PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical. PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project collaboration with Otsuka Pharmaceutical Co., the world-leading pharmaceutical company dedicated to the research and development of highly-innovative… Read More
Spotlight on Abzena’s Developability Platform during Antibody Engineering & Therapeutics 2019. New service reduces the risk, expenditure and time required for the later stages of antibody development Abzena is showcasing its new Developability Service, enabling biotechnology and pharmaceutical companies to improve lead selection and… Read More
Carterra closes financing round for continued growth of the LSA platform for next generation antibody dscovery. Carterra has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption… Read More
Advanced BioMatrix has acquired the HyStem line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan. HyStem® kits are based on innovative thiolated hyaluronic acid technology. With HyStem®, researchers can create customizable 3D hydrogels for culturing cells whose natural environment is rich in hyaluronic acid. Read More
TTP Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science applications, has announced its corporate name change to SPT Labtech effective from January 6, 2020. The change of name is a contractual requirement of its divestment from… Read More
The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More
Grey Wolf Therapeutics completes £2.5 million ($3.3 million) Series A2 financing to accelerate development of therapies targeting ERAP2. Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system. Grey Wolf Therapeutics, a drug discovery… Read More
Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients. Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of… Read More
State-of-the art facility is home to the company’s next-generation, fully automated platform for drug discovery. Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford,… Read More
The vaccine is currently being evaluated in Phase 3 clinical testing. The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More